Share
.webp)
.webp)
.webp)
.webp)
Rajiv Patni
Lexeo Therapeutics, Inc., has announced a series of strategic executive appointments to support the advancement of its pipeline into late-stage clinical development.
“The growing expertise within Lexeo’s leadership has been instrumental in driving some of the most impactful clinical programs, drug approvals, and product launches in rare disease and precision cardiovascular medicine,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. “We are excited to leverage the thought leadership and operational experience of our newly appointed executives as we transition our pipeline towards late-stage clinical studies.”
The new appointment include:
Rajiv Patni, MD has been appointed Senior Advisor to the Chief Executive Officer and Board of Directors. Dr. Patni brings a wealth of experience from his previous role as Chief Research and Development Officer at Reata Pharmaceuticals, where he played a key role in securing FDA approval for Skyclarys, the first approved therapy for Friedreich’s ataxia. He also contributed to the successful acquisitions of several biopharmaceutical companies and has overseen the development of 21 new chemical entities in multiple therapeutic areas.
